Medical Affairs Professional Society (MAPS)’s Post

In the latest episode of the #ParexelBiotech podcast series, “De-Risking Drug Development,” our host, Paul Bridges, and colleagues focus on critical decision points in phases IIb & III that can ultimately determine the success of your product. Join Sangeeta Budhia, Sinan Sarac, and Amy Pace as they discuss how to accelerate development and opportunities to differentiate your product through innovative and adaptive trial designs. Learn about the importance of integrated evidence planning and the critical role of early value story development alongside target product profile (TPP) planning. Mitigate development risks and stand out among competitors by planning ahead. Listen here: https://lnkd.in/eiutsSwF #Biotech #TrialDesign #ClinicalDevelopment

In the latest episode of the #ParexelBiotech podcast series, “De-Risking Drug Development,” our host, Paul Bridges, and colleagues focus on critical decision points in phases IIb & III that can ultimately determine the success of your product. Join Sangeeta Budhia, Sinan Sarac, and Amy Pace as they discuss how to accelerate development and opportunities to differentiate your product through innovative and adaptive trial designs. Learn about the importance of integrated evidence planning and the critical role of early value story development alongside target product profile (TPP) planning. Mitigate development risks and stand out among competitors by planning ahead. Listen here: https://lnkd.in/drgWASg5 #Biotech #TrialDesign #ClinicalDevelopment

In the latest episode of the #ParexelBiotech podcast series, “De-Risking Drug Development,” our host, Paul Bridges, and colleagues focus on critical decision points in phases IIb & III that can ultimately determine the success of your product. Join Sangeeta Budhia, Sinan Sarac, and Amy Pace as they discuss how to accelerate development and opportunities to differentiate your product through innovative and adaptive trial designs. Learn about the importance of integrated evidence planning and the critical role of early value story development alongside target product profile (TPP) planning. Mitigate development risks and stand out among competitors by planning ahead. Listen here: https://lnkd.in/eTbgnSXb #Biotech #TrialDesign #ClinicalDevelopment

In the latest episode of the #ParexelBiotech podcast series, “De-Risking Drug Development,” our host, Paul Bridges, and colleagues focus on critical decision points in phases IIb & III that can ultimately determine the success of your product. Join Sangeeta Budhia, Sinan Sarac, and Amy Pace as they discuss how to accelerate development and opportunities to differentiate your product through innovative and adaptive trial designs. Learn about the importance of integrated evidence planning and the critical role of early value story development alongside target product profile (TPP) planning. Mitigate development risks and stand out among competitors by planning ahead. Listen here: #Biotech #TrialDesign #ClinicalDevelopment

🚀 We're excited to announce that The BioHub Podcast now has its own LinkedIn page! It’s been a long time coming, and we're thrilled to connect with you here as we dive into Season 2. 👉 Follow us for the latest updates, exclusive insights, and conversations with the brightest minds in Biotech and Pharma. Stay tuned and stay inspired! #BioHubPodcast #Biotech #Pharma #Innovation #Podcast

🚨New Podcast Alert🚨 Sameer Lal, Sr. Vice President, Enterprise Medical Solutions at Indegene, discusses with Miranda Schmalfuhs the findings from their new study about Reshaping #Pharmacovigilance in the age of AI, digital/ #generativeai opportunities, how quickly the industry is adopting this technology, and much more. Listen to this podcast here: https://lnkd.in/evAMwp4d OR on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts. #pharmaceutical #pharmaceuticalindustry

I had the best conversation with Sameer Lal, Senior Vice President, Enterprise Medical Solutions at Indegene, or the King of Analogies as I have deemed him (example below). Sameer and I discussed his company's new study 'Reshaping Pharmacovigilance in the Age of AI', what's holding the industry back from #artificialintelligence / #machinelearning adoption, how to keep/utilize existing employees when adopting AI/ML technologies, and so much more. Give a listen...

Thank you, Miranda Schmalfuhs and Pharmaceutical Executive team! This is the first time someone has called me the King of Analogies... I really enjoyed our conversation as well, discussing findings from Indegene's new study about reshaping Pharmacovigilance in the age of AI, digital/generative AI opportunities, how quickly the industry is adopting this technology, and much more. Indegene World Drug Safety Congress Americas World Drug Safety Congress Europe

In the latest episode of the #ParexelBiotech podcast series, “De-Risking Drug Development,” our host, Paul Bridges, and colleagues focus on critical decision points in phases IIb & III that can ultimately determine the success of your product. Join Sangeeta Budhia, Sinan Sarac, and Amy Pace as they discuss how to accelerate development and opportunities to differentiate your product through innovative and adaptive trial designs. Learn about the importance of integrated evidence planning and the critical role of early value story development alongside target product profile (TPP) planning. Mitigate development risks and stand out among competitors by planning ahead. Listen here: https://lnkd.in/gm4P23Ex #Biotech #TrialDesign #ClinicalDevelopment

Our latest podcast episode explores how pharma companies are approaching AI, with Dan Seewald of Deliberate Innovation. Here's a snippet... https://hubs.ly/Q02k9Gy10 Subscribe to Innovation Answered on your favorite podcasting platform / app! #AI #pharmaceuticals #innovation